ARTICLE | Company News
FDA grants Imbruvica broader CLL approval
March 5, 2016 1:23 AM UTC
FDA approved Imbruvica ibrutinib as a first-line treatment for chronic lymphocytic leukemia (CLL). AbbVie Inc. (NYSE:ABBV) and Johnson & Johnson (NYSE:JNJ) share U.S. rights to the drug. ...